학술논문
Regen-Cov and Covid-19, Update on the Drug Profile and Fda Status: A Mini-Review and Bibliometric Study.
Document Type
Academic Journal
Author
Mawazi SM; School of Pharmacy, Management & Science University (MSU), Selangor, Malaysia.; Khan J; School of Pharmacy, Management & Science University (MSU), Selangor, Malaysia.; Othman N; School of Pharmacy, Management & Science University (MSU), Selangor, Malaysia.; Department of Clinical and Hospital Pharmacy, College of Pharmacy, Taibah University, Saudi Arabia.; Alolayan SO; Department of Clinical and Hospital Pharmacy, College of Pharmacy, Taibah University, Saudi Arabia.; Alahmadi YM; Department of Clinical and Hospital Pharmacy, College of Pharmacy, Taibah University, Saudi Arabia.; Thagfan SSA; Department of Clinical and Hospital Pharmacy, College of Pharmacy, Taibah University, Saudi Arabia.; Helmy SA; Department of Clinical and Hospital Pharmacy, College of Pharmacy, Taibah University, Saudi Arabia.; Department of Pharmaceutics, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt.; Marzo RR; Department of Community Medicine, International Medical School, Management and Science University, Selangor, Malaysia.
Source
Publisher: SAGE Publications Country of Publication: United States NLM ID: 101580775 Publication Model: eCollection Cited Medium: Print ISSN: 2279-9028 (Print) Linking ISSN: 22799028 NLM ISO Abbreviation: J Public Health Res Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2279-9028
Abstract
COVID-19 is caused by coronavirus (SARS-CoV-2) is a worldwide health crisis. This severe acute respiratory syndrome was declared an outbreak after the first case was reported in Wuhan, the capital city of Hubei Province in China. On March 11th, 2020, the World Health Organization (WHO) declared it as a pandemic. The pharmaceutical treatment of COVID-19 has garnered significant critical attention due to the unavailability of medications to treat COVID-19. Recently, researchers have shown an increased interest in the monoclonal antibody drugs to treat COVID-19 especially REGEN-COV (casirivimab and imde-vimab). This review aims to highlight the relation between the drug and COVID-19 and the recently updated information on the monoclonal antibody REGEN-COV from the U.S. Food and Drug Administration and other authorities. It is also designed to focus on the bibliometric data of REGEN-COV for the last three years (2020, 2021, and 2021) in PubMed and Google Scholar.
Competing Interests: Conflict of interest: The authors declare no conflict of interest.
(© 2021 SAGE Publications Ltd unless otherwise noted.)
Competing Interests: Conflict of interest: The authors declare no conflict of interest.
(© 2021 SAGE Publications Ltd unless otherwise noted.)